Pricing Log in Create free account

Contineum Therapeutics, Inc. (CTNM) vs Surrozen, Inc. (SRZN)

Contineum Therapeutics, Inc. and Surrozen, Inc. are both Biotechnology companies. Contineum Therapeutics, Inc. and Surrozen, Inc. are of similar size ($297.2M and $294.7M). Contineum Therapeutics, Inc. has the higher net margin (0.00% vs −2,887.1%) and the lower return on invested capital (−1,334.4% vs 0.00%). Across the 11 metrics below, Contineum Therapeutics, Inc. leads on 7 and Surrozen, Inc. on 4.

Valuation

Metric CTNM SRZN Biotechnology median
P/E n/m n/m 8.50
P/S n/m 23.78 9.71
P/B 1.10 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 14.92 9.21
Earnings yield (24.64%) (159.31%) (33.15%)
Free cash flow yield (20.33%) (12.78%) (25.50%)

Profitability

Metric CTNM SRZN Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (385.28%) 0.00%
Net margin 0.00% (2,887.07%) 0.00%
Free cash flow margin 0.00% (303.92%) 0.00%
Return on equity (28.01%) 387.44% (56.36%)
Return on assets (26.57%) (304.47%) (48.04%)
Return on invested capital (1,334.41%) 0.00% 0.00%

Growth

Metric CTNM SRZN Biotechnology median
Revenue growth (TTM) — (8.79%) 6.02%
EPS growth (last fiscal year) 0.46% (49.38%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CTNM SRZN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 37.17 12.14 4.72
Net debt to EBITDA 3.88 2.15 0.96

Dividend

Metric CTNM SRZN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CTNM SRZN Biotechnology median
Market cap 297.21m 294.66m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack